Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial
- 23 September 2013
- journal article
- research article
- Published by Elsevier BV in The Lancet Neurology
- Vol. 12 (11), 1059-1067
- https://doi.org/10.1016/s1474-4422(13)70221-7
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trialThe Lancet Neurology, 2013
- The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trialsAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013
- Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trialJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiencyBrain Research, 2012
- Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trialThe Lancet Neurology, 2010
- Mitochondria: A therapeutic target in neurodegenerationBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?☆Advanced Drug Delivery Reviews, 2009
- Lithium delays progression of amyotrophic lateral sclerosisProceedings of the National Academy of Sciences, 2008
- Mitochondrial dysfunction and oxidative stress in neurodegenerative diseasesNature, 2006
- A Controlled Trial of Riluzole in Amyotrophic Lateral SclerosisNew England Journal of Medicine, 1994